The Jerusalem Post - Israel News

Optalgin teva

Teva's new migraine drug helps contain profit fall

Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.

MAY 5, 2019
ByREUTERS
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019